A 19.8% placebo-adjusted BMI reduction over 52 weeks is not a number Rhythm can afford to bury — it is the entire commercial argument for why setmelanotide deserves reimbursement across a fragmented European payer landscape where rare-disease pricing negotiations routinely drag two to three years past authorization. The European Commission has now granted marketing authorization for setmelanotide in acquired hypothalamic obesity in adults and children aged four and older, mirroring the FDA approval secured in March. The patient population is small — Rhythm estimates roughly 10,000 people in Europe — but the clinical signal is unusually clean for a rare obesity indication, with pediatric patients achieving a 20.2% placebo-adjusted BMI reduction and adults hitting 19.2%, both at the one-year mark.
The strategic tension here is the gap between authorization and revenue. Rhythm has explicitly flagged that commercial launches in Europe are not expected until 2027, which means the company must now run parallel health technology assessment processes across individual EU member states — each with its own evidentiary standards, willingness-to-pay thresholds, and appetite for rare neuroendocrine disease budgets. Germany and France will move faster than most, but neither is guaranteed to reimburse at a price that sustains the economics Rhythm needs from a market of this size. The UK’s MHRA has already authorized setmelanotide for other MC4R pathway indications, which gives Rhythm a negotiating foothold, but acquired hypothalamic obesity is a distinct condition with a distinct evidence package and will face its own NICE review.
Rhythm’s broader asset architecture matters here too. With bivamelagon and RM-718 in the pipeline and a widening indication roster for setmelanotide across rare neuroendocrine diseases, the company is building toward a platform story rather than a single-drug narrative. That framing helps with investors but is largely irrelevant to a German GBA committee deciding whether a 10,000-patient European population justifies setmelanotide’s price point against a backdrop of aggressive GLP-1 spending pressure across European health systems.
The single marker to track is the first national reimbursement decision in a major EU market — Germany or France — because that outcome will effectively anchor pricing expectations for every subsequent country negotiation and determine whether the 2027 launch timeline holds any commercial weight.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
